Negative naloxone effects in schizophrenic patients.
On the basis of the hypothesis that the opiate-like neuropeptides, such as beta-endorphin, may be involved in the etiology of schizophrenic symptoms, naloxone 1,2 mg and placebo were administered intravenously to 8 schizophrenic patients, using a double-blind, crossover design. Naloxone was not found to be different from placebo in effecting schizophrenic symptoms, including hallucinations and delusions.
D000328:Adult; D010054:Brief Psychiatric Rating Scale; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006212:Hallucinations / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology / Q000627:therapeutic use*; D010919:Placebos; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D010919:Placebos; D009270:Naloxone